BDX

Business Context and Reporting Period

Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended June 30, 2006
Business Overview: BD is a medical technology company operating in three segments: BD Medical, BD Diagnostics, and BD Biosciences. The company manufactures medical supplies, devices, laboratory equipment, and diagnostic products.

Key Financial Metrics

Note: Debt figures represent the sum of Short-term debt ($309.0M) and Long-Term Debt ($954.0M) as of June 30, 2006.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 7% in the quarter and 8% for the nine-month period compared to the prior year. Growth was driven by volume increases of approximately 8%, partially offset by a 1% unfavorable impact from foreign currency translation.
• Acquisition Impact: On February 14, 2006, BD acquired GeneOhm Sciences, Inc. for $231.1 million. This resulted in a non-deductible charge of $53.3 million for acquired in-process research and development, recorded in R&D expenses.
• Segment Performance:
  • Medical: Revenues up 8% (quarter) and 9% (nine months), driven by Diabetes Care and safety-engineered devices.
  • Diagnostics: Revenues up 6% (quarter) and 5% (nine months). Operating income margin was reduced by the GeneOhm acquisition charge.
  • Biosciences: Revenues up 9% (quarter) and 9% (nine months), with improved operating margins due to manufacturing efficiency.
• Costs and Expenses: R&D expenses increased significantly (16% in the quarter, 42% for nine months) primarily due to the GeneOhm acquisition charge. Share-based compensation expense also increased year-over-year.
• Debt and Liquidity: Total debt-to-capitalization ratio decreased to 25.8% from 27.3% at the prior fiscal year-end. Cash and equivalents decreased by $321.9 million over the nine-month period, largely due to the GeneOhm acquisition and stock repurchases.

Guidance, Outlook, and Risks

• Outlook: Management expects gross profit margins to improve by 50 to 60 basis points in fiscal 2006. Selling and administrative expenses are expected to decrease by about 50 basis points as a percentage of revenue. R&D expenses are anticipated to increase approximately 32% for the full year, with 19% attributable to the GeneOhm charge.
• Capital Allocation: The company repurchased $433.0 million of common stock in the first nine months of 2006. Approximately 7.3 million shares remain authorized for repurchase. Capital expenditures are expected to be in the $450 million range for fiscal 2006.
• Risks and Contingencies:
  • Legal Proceedings: BD is involved in ten consolidated antitrust class action lawsuits and a separate suit by UltiMed, Inc. regarding insulin syringes. Management believes it has meritorious defenses but notes potential for material adverse effects if outcomes are unfavorable.
  • Raw Materials: Higher resin costs due to oil prices may impact future results, though management expects to mitigate this through margin improvements and cost reductions.
  • Regulatory: Risks include FDA approvals for new products (e.g., inhaled insulin) and changes in healthcare reimbursement policies.

Investor Verification Checklist

• Verify the integration progress and revenue contribution of the GeneOhm acquisition.
• Monitor the status of the ten consolidated antitrust class action lawsuits and the UltiMed litigation.
• Track the impact of rising resin/raw material costs on gross margins versus the company's cost reduction initiatives.
• Confirm the execution of the remaining $450 million capital expenditure plan for fiscal 2006.
• Review the effectiveness of foreign currency hedging strategies given the 1% unfavorable translation impact reported.